Doing the possible: harm reduction, injecting drug use and blood borne viral infections in Australia

the necessity of enhanced harm reduction programs to prevent blood-borne infections amongst injection drug users

Harm reduction among injecting drug users — evidence of effectiveness

This chapter synthesises and evaluates the available direct evidence relating to the impact of needle and syringe programmes (NSPs), opioid substitution treatment (OST), drug consumption rooms (DCRs), and peer naloxone distribution (PND) on HIV/hepatitis C (HCV) incidence/prevalence, injecting risk behaviour and overdose-related mortality. To achieve this, we conducted a review of reviews; a sy...

Drug use and harm reduction in Afghanistan

Opium has been cultivated in Afghanistan since 1100 A.D., although production has steadily increased since 1979. Currently, Afghanistan produces three-quarters of the global opium supply, with injection drug use and HIV currently following the opium trade route through Central Asia. Although systematic studies are lacking, heroin use appears to be on the rise in Afghanistan. The purpose of this...

The epidemics of injecting drug use and blood-borne disease: a public health perspective.

Public injecting and the need for 'safer environment interventions' in the reduction of drug-related harm.

BACKGROUND One key structural dimension in the distribution of drug-related harm associated with injecting drug use is the injecting environment. Epidemiological evidence associates elevated blood-borne viral risk with injecting in 'public' and 'semipublic' environments. Yet the quality of evidence on public injecting and related viral risk is variable, and is lacking in many countries such as ...